LifeTech Scientific Corporation was established in Shenzhen, China

HeartR™ PDA Occluder was approved by NMPA in China, becoming the first product successfully marketed by the company

HeartR™ ASD Occluder was approved by NMPA in China

Ankura™ TAA\AAA Stent Graft System and HeartR™ VSD Occluder were approved by NMPA in China

Aegisy™ Vena Cava Filter was approved by NMPA in China

The company received a venture capital investment from the United States

SteerEase™ Introducer was approved by NMPA in China

The company was accredited as a national high-tech enterprise in China

The company expanded its business into India market and incorporated Lifetech Scientific India Private Limited into the LifeTech family

Aegisy™ Vena Cava Filter obtained the CE mark in EU, becoming the first product of the company to receive one

Cera™ Occluder series and SteerEase™ Introducer obtained the CE mark in EU

SeQure™ Snare System received FDA approval in the United States, becoming the first product of the company to receive one

Fustar™ Steerable Introducer, Cera™ Vascular Plug System, Acumark™ Sizing Balloon, Cera™ Multi-Fenestrated ASD Occluder and SeQure™ Snare System obtained the CE mark in EU

LifeTech Scientific Corporation was listed on the Hong Kong Stock Exchange (Stock Code: 1302.HK)

The company incorporated LifeTech Scientific (Europe) Coöperatief U.A. to further explore the European market

Fustar™ Steerable Introducer received FDA approval in the United States

CeraFlex™ Occluder series and Vascular Plugs, Ankura™ Stent Graft System obtained the CE mark in EU

The company established a strategic partnership with Medtronic, Inc.

The company incorporated LifeTech Scientific (Netherlands) B.V. into the LifeTech family

Cera™ PDA Occluder and ASD Occluder were approved by NMPA in China

HeartR™ Occluder series, Cera™/CeraFlex™/IrisFit™ PFO Occluders and LawMax™ Dilator obtained the CE mark in EU

Cera™ VSD Occluder was approved by NMPA in China

LawMax™ Dilator received FDA approval in the United States

Fustar™ Steerable Introducer was approved by NMPA in China

The company has been included in the Hang Seng Index

The company incorporated Lifetech Scientific America Corporation to add to its list of international subsidiaries

The company has been included in the Shenzhen-Hong Kong Stock Connect Programs

The company established a subsidary in Hong Kong and Greece, respectively

LAmbre™ LAA Closure System and GoldenFlow™ Peripheral Bare Stent System obtained the CE mark in EU

SteerNavi™ Introducer was approved by NMPA in China

The company commercialized HeartTone™ Implantable Cardiac Pacemakers in China market with the cooperation of Medtronic Inc.

LAmbre™ LAA Closure System, SeQure™ Snare System, LawMax™ Dilator and Ankura™ II Stent Graft System were approved by NMPA in China

The company established a strategic partnership with Ally Bridge Group, a global life science-focused investment firm

KONAR-MF™ VSD Occluder obtained the CE mark in EU

The company established a joint venture (JV) with Quantum Surgical SAS and Ally Bridge Group for commercialization of the Epione®, a new category of oncology robotics in China market

The company incorporated LifeTech Scientific Deutschland GmbH to further expand its business in the heart of Europe

LAmbre™ LAA Closure System obtained FDA approval for the pre-market clinical study in the United States

Aelark™ Vena Cava Filter System was approved by NMPA in China

LAmbre™ LAA Closure System obtained FDA approval for an investigator-initiated pre-market clinical trial in the United States

HeartR™ II ASD Occluder, Fustar™ mini Steerable Catheter, FiQure™ Vena Cava Filter Retrieval System, ZoeTrack™ Guidewire, FemCross™ 18 Peripheral Balloon Dilatation Catheter, Futhrough™ Stent Graft Balloon Catheter were approved by NMPA in China

Futhrough™ Endovascular Needle System obtained the CE mark in EU

The invention patent “LAA Occluder” won the WIPO-CNIPA Award for Chinese Outstanding Patented Invention

The company and Medtronic Inc. expanded strategic collaboration to open a new chapter of domestically-made MRI-conditional pacemakers in China

G-iliac™ Iliac Artery Bifurcation Stent Graft System, Yuranos™ Abdominal Aortic Stent Graft System, LAxible™ LAA Occluder, LAnavi™ Jointed Steerable Introducer, OKcurve™ Steerable Delivery System, Freepath™ Guidance System and iCable™ Delivery Cable were approved by NMPA in China

IBS Angel™ Iron Bioresorbable Scaffold System obtained registration approval from Malaysian Medical Device Authority (MDA)

Xuper™ Open Surgery Stent Graft System obtained the CE mark in EU

An FDA-approved investigator-initiated pre-market clinical trial of LAmbre™ Plus LAA Closure System obtained medical insurance coverage in the United States

Fitaya™ Vena Cava Filter System, FemCross™ 35 Peripheral Balloon Dilatation Catheter and Ankura™ llc Stent Graft System were approved by NMPA in China